Concordia International Corp (TSE:CXR) (NASDAQ:CXRX) insider Alternative Asset Manage Solus sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of C$26.06, for a total value of C$26,060.00.

Shares of CXR stock opened at C$24.50 on Tuesday. Concordia International Corp has a 1 year low of C$19.02 and a 1 year high of C$486.00.

Concordia International (TSE:CXR) (NASDAQ:CXRX) last issued its quarterly earnings results on Wednesday, August 8th. The company reported C($175.76) earnings per share (EPS) for the quarter, missing the consensus estimate of C($27.27) by C($148.49). The company had revenue of C$180.02 million during the quarter.

Separately, Bloom Burton reiterated a “hold” rating on shares of Concordia International in a research note on Tuesday, September 11th.

About Concordia International

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Further Reading: Do Tariffs Work?

Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with's FREE daily email newsletter.